László Gulácsi
The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project
A Wimo, L Jönsson, A Gustavsson, D McDaid, K Ersek, J Georges, ...
International journal of geriatric psychiatry 26 (8), 825-832, 2011
Statement of the European Pressure Ulcer Advisory Panel-Pressure Ulcer Classification: Differentiation Between Pressure Ulcers and Moisture Lesions.
T Defloor, L Schoonhoven, J Fletcher, K Furtado, HW Heyman, ...
The changing landscape of biosimilars in rheumatology
T Dörner, V Strand, P Cornes, J Gonçalves, L Gulácsi, J Kay, TK Kvien, ...
Annals of the rheumatic diseases 75 (6), 974-982, 2016
The state of the art in European research on reducing social exclusion and stigma related to mental health: a systematic mapping of the literature
S Evans-Lacko, E Courtin, A Fiorillo, M Knapp, M Luciano, AL Park, ...
European Psychiatry 29 (6), 381-389, 2014
Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003
M Pentek, C Horváth, I Boncz, Z Falusi, E Toth, A Sebestyen, I Májer, ...
Osteoporosis international 19 (2), 243-249, 2008
The implementation of quality management systems in hospitals: a comparison between three countries
C Wagner, L Gulácsi, E Takacs, M Outinen
BMC health services research 6 (1), 50, 2006
Access to biologic treatment for rheumatoid arthritis in Central and Eastern European (CEE) countries
E Orlewska, I Ancuta, B Anic, C Codrenau, N Damjanov, P Djukic, ...
Medical science monitor: international medical journal of experimental and …, 2011
Issues for countries considering introducing the “fourth hurdle”: the case of Hungary
L Gulácsi, I Boncz, M Drummond
International Journal of Technology Assessment in Health Care 20 (3), 337-341, 2004
Adherence to biologic DMARD therapies in rheumatoid arthritis
T Koncz, M Pentek, V Brodszky, K Ersek, E Orlewska, L Gulacsi
Expert opinion on biological therapy 10 (9), 1367-1378, 2010
Informal payments for healthcare services and short‐term effects of the introduction of visit fee on these payments in Hungary
P Baji, M Pavlova, L Gulácsi, HC Zsófia, W Groot
The International journal of health planning and management 27 (1), 63-79, 2012
Biosimilars for the management of rheumatoid arthritis: economic considerations
L Gulácsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Péntek
Expert review of clinical immunology 11 (sup1), 43-52, 2015
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ...
The European Journal of Health Economics 15 (1), 111-119, 2014
User fees for public health care services in Hungary: Expectations, experience, and acceptability from the perspectives of different stakeholders
P Baji, M Pavlova, LÓ Gulácsi, W Groot
Health Policy 102 (2-3), 255-262, 2011
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
L Gulácsi, AM Rotar, M Niewada, O Löblová, F Rencz, G Petrova, I Boncz, ...
The European journal of health economics 15 (1), 13-25, 2014
A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia
V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi
Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016
Cost-of-illness of patients with systemic sclerosis in a tertiary care centre
T Minier, M Péntek, V Brodszky, A Ecseki, K Kárpáti, A Polgár, L Czirják, ...
Rheumatology 49 (10), 1920-1928, 2010
Quality management and patient safety: Survey results from 102 Hungarian hospitals
P Makai, N Klazinga, C Wagner, I Boncz, L Gulacsi
Health policy 90 (2-3), 175-180, 2009
Budget-impact analyses
E Orlewska, L Gulácsi
Pharmacoeconomics 27 (10), 807-827, 2009
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe
F Rencz, M Péntek, M Bortlik, E Zagorowicz, T Hlavaty, A ¦liwczyński, ...
World Journal of Gastroenterology: WJG 21 (6), 1728, 2015
Comparison of the Psoriatic Arthritis Quality of Life (PsAQoL) questionnaire, the functional status (HAQ) and utility (EQ-5D) measures in psoriatic arthritis: results from a …
V Brodszky, M Péntek, PV Bálint, P Géher, O Hajdu, L Hodinka, G Horvath, ...
Scandinavian journal of rheumatology 39 (4), 303-309, 2010
A rendszer jelenleg nem tudja elvégezni a műveletet. Próbálkozzon újra később.
Cikkek 1–20